Nido Biosciences
Even promising biotech startups with significant funding can fail if their core product does not demonstrate efficacy in clinical trials, highlighting the high-risk nature of drug development.
Nido Biosciences was a Biotechnology startup founded in 2020 in USA. It raised $109 million before collapsing in 2026 — 6 years of runway burned. IdeaProof's AI Failure Score: 0/100, driven by drug failed phase ii clinical trial. The shutdown affected employees, investors, and the broader Biotechnology ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Nido Biosciences fail?
Nido Biosciences failed in 2026 after 6 years of operation, losing $109 million in raised capital. The root cause was drug failed phase ii clinical trial. Key lesson: Even promising biotech startups with significant funding can fail if their core product does not demonstrate efficacy in clinical trials, highlighting the high-risk nature of drug development.
2020 → 2026
$109 million
Biotechnology
USA
Full Analysis
Nido Biosciences, founded in 2020, aimed to develop a drug for spinal and bulbar muscular atrophy (Kennedy's disease). The company successfully raised $109 million across Seed, Series A, and Series B rounds in 2023, attracting investments from prominent firms like 5AM Ventures, Abingworth, Bessemer Venture Partners, and even pharmaceutical giant Eli Lilly. Despite being hailed as a 'Most Promising Next-Generation Biotech Star' in early 2024, Nido Biosciences announced its closure in early 2026. The primary reason for its failure was the lack of efficacy shown by its lead drug candidate, NIDO-361, in its global Phase II clinical trial. This failure led to the termination of the core pipeline and ultimately the company's shutdown, illustrating the critical dependence of biotech companies on successful clinical outcomes.
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Nido Biosciences.